No. of patients
|
195
|
95
|
100
| |
Age, years (SD)
|
73.8 (13.5)
|
75.2 (12.3)
|
72.4 (14.6)
|
0.142
|
Sex
|
0.069
|
Male
|
138 (70.8%)
|
73 (76.8%)
|
65 (65%)
| |
Female
|
57 (29.2%)
|
22 (23.2%)
|
35 (35%)
| |
BMI (SD)
|
22.3 (4.6)
|
21.7 (4.8)
|
22.8 (4.3)
|
0.106
|
Smoking
|
78 (40%)
|
40 (42.1%)
|
38 (38%)
|
0.559
|
Comorbidities
| |
Diabetes
|
57 (29.2%)
|
28 (29.5%)
|
29 (29%)
|
0.942
|
Malignancies
|
33 (16.9%)
|
24 (25.3%)
|
9 (9%)
|
0.002
|
Renal insufficiency (CCr < 30)
|
21 (10.8%)
|
10 (10.5%)
|
11 (11%)
|
0.915
|
Chronic liver diseases
|
16 (8.2%)
|
3 (3.2%)
|
13 (13%)
|
0.017
|
Heart failure
|
17 (8.7%)
|
8 (8.4%)
|
9 (9%)
|
0.886
|
CR-GNB culture sources
| |
Respiratory specimens
|
157 (80.5%)
|
75 (78.9%)
|
82 (82%)
|
0.591
|
Urine
|
11 (5.6%)
|
6 (6.3%)
|
5 (5%)
|
0.691
|
Blood
|
10 (5.1%)
|
4 (4.2%)
|
6 (6%)
|
0.571
|
Others
|
17 (8.7%)
|
10 (10.5%)
|
7 (7%)
|
0.383
|
CR-GNB species
| |
CRAB
|
141 (72.3%)
|
64 (67.4%)
|
77 (77%)
|
0.270
|
CRE
|
45 (23.1%)
|
28
(29.5%)
|
17 (17%)
|
0.051
|
CRPA
|
9 (4.6%)
|
3 (3.2%)
|
6 (6%)
|
0.344
|
Laboratory results (Mean, SD)
| |
Leukocytes (× 109 per L)
|
13.2 (9.0)
|
13.2 (8.3)
|
13.3 (9.7)
|
0.935
|
CRP (mg/dL)
|
10.0 (6.5)
|
10.3 (7.6)
|
9.6 (5.9)
|
0.464
|
Albumin level (median, IQR)
|
2.7 (2.4–3.0)
|
2.8 (2.5–3.1)
|
2.6 (2.3–2.9)
|
0.017
|
Concomitant nephrotoxins
| |
Aminoglycoside
|
22 (11.3%)
|
15 (15.8%)
|
7 (7%)
|
0.052
|
Vancomycin
|
20 (10.3%)
|
13 (13.7%)
|
7 (7%)
|
0.124
|
Intravenous contrast agent
|
39 (20.0%)
|
17 (17.9%)
|
22 (22%)
|
0.474
|
Disease severity
| |
APACHEII scores (median, IQR)b
|
24 (19–30)
|
25 (20–30)
|
24 (19–30)
|
0.768
|
Respiratory failured
|
175 (89.7%)
|
83 (87.4%)
|
92 (92%)
|
0.287
|
Septic shockd
|
61 (31.3%)
|
33 (34.7%)
|
28 (28%)
|
0.310
|
Intravenous colistin
| |
Daily dosage (MIU) (median, IQR)
|
8 (4–10)
|
8 (4–10)
|
8 (4–10)
|
0.814
|
Treatment duration (median, IQR)
|
7 (4–12)
|
7 (4–12)
|
7 (4–12)
|
0.782
|
Accumulated dosage (MIU) (median, IQR)
|
48 (28–80)
|
48 (28–64)
|
48 (24–88)
|
0.956
|
Inappropriate colistin dosage
|
23 (11.8%)
|
7 (7.4%)
|
16 (16%)
|
0.062
|